CD8A and colorectal cancer: In colorectal cancer, AS-IV strongly inhibits Wnt/β-catenin signaling, reverses EMT, and modulates gut microbiota, whereas APS activates CD8+ T cell–mediated immunity and serves as an adjuvant in nanoparticle-based vaccines.